Multidisciplinary Management of Nonfunctional Neuroendocrine Tumor of the Pancreas

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 Mar 23

PMID 27003988

Citations 4

Authors

Ian W Folkert

Paul Hernandez

Robert E Roses

Affiliations

Soon will be listed here.

Abstract

Pancreatic neuroendocrine tumors (PNETs) are a rare and diverse group of tumors; nonfunctional (NF) PNETs account for the majority of cases. Most patients with NF-PNETs have metastatic disease at the time of presentation. A variety of treatment modalities exist, including medical, liver directed, and surgical treatments. Aggressive surgical management is associated with prolonged survival, however available data are limited by selection bias and the frequent combination of PNETs with carcinoid tumors. Although few patients with metastatic disease will be cured, application of currently available therapies in a multidisciplinary setting can lead to excellent outcomes with prolonged patient survival.

Citing Articles

Coexisting giant splenic artery aneurysm and non-functioning pancreatic neuroendocrine tumor.

Yalkin O, Uzunoglu M, Altintoprak F, Muhtaroglu A Pak J Med Sci. 2020; 36(4):843-845.

PMID: 32494285 PMC: 7260904. DOI: 10.12669/pjms.36.4.1869.

A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.

Zaidi M, Lopez-Aguiar A, Switchenko J, Lipscomb J, Andreasi V, Partelli S Ann Surg. 2019; 270(3):422-433.

PMID: 31283562 PMC: 6697205. DOI: 10.1097/SLA.0000000000003461.

Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target.

Kelgiorgi D, Dervenis C F1000Res. 2017; 6:663.

PMID: 28529726 PMC: 5428491. DOI: 10.12688/f1000research.10188.1.

Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.

Herring M, Huynh L, Duh M, Vekeman F, Tiew A, Neary M Med Oncol. 2017; 34(5):88.

PMID: 28393314 DOI: 10.1007/s12032-017-0927-0.

References

Kahl S, Malfertheiner P . Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004; 18(5):947-55. DOI: 10.1016/j.bpg.2004.06.028. View

Casanovas O, Hicklin D, Bergers G, Hanahan D . Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309. DOI: 10.1016/j.ccr.2005.09.005. View

Lee L, Grant C, Salomao D, Fletcher J, Takahashi N, Fidler J . Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012; 152(6):965-74. DOI: 10.1016/j.surg.2012.08.038. View

Fernandez-Cruz L, Molina V, Vallejos R, Jimenez Chavarria E, Lopez-Boado M, Ferrer J . Outcome after laparoscopic enucleation for non-functional neuroendocrine pancreatic tumours. HPB (Oxford). 2012; 14(3):171-6. PMC: 3371199. DOI: 10.1111/j.1477-2574.2011.00422.x. View

Gaujoux S, Partelli S, Maire F, DOnofrio M, Larroque B, Tamburrino D . Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2013; 98(12):4784-9. DOI: 10.1210/jc.2013-2604. View

Norton J, Warren R, Kelly M, Zuraek M, Jensen R . Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003; 134(6):1057-63. DOI: 10.1016/j.surg.2003.07.025. View

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

Gomez-Rivera F, Stewart A, Arnoletti J, Vickers S, Bland K, Heslin M . Surgical treatment of pancreatic endocrine neoplasms. Am J Surg. 2007; 193(4):460-5. DOI: 10.1016/j.amjsurg.2006.10.016. View

Dussol A, Joly M, Vercherat C, Forestier J, Hervieu V, Scoazec J . Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice. Cancer. 2015; 121(19):3428-34. DOI: 10.1002/cncr.29517. View

10.

Akyildiz H, Mitchell J, Milas M, Siperstein A, Berber E . Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010; 148(6):1288-93. DOI: 10.1016/j.surg.2010.09.014. View

11.

Kent 3rd R, Van Heerden J, Weiland L . Nonfunctioning islet cell tumors. Ann Surg. 1981; 193(2):185-90. PMC: 1345039. DOI: 10.1097/00000658-198102000-00010. View

12.

Franko J, Feng W, Yip L, Genovese E, Moser A . Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg. 2009; 14(3):541-8. DOI: 10.1007/s11605-009-1115-0. View

13.

Schurr P, Strate T, Rese K, Kaifi J, Reichelt U, Petri S . Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007; 245(2):273-81. PMC: 1876988. DOI: 10.1097/01.sla.0000232556.24258.68. View

14.

Hodul P, Strosberg J, Kvols L . Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?. Cancer Control. 2008; 15(4):314-21. DOI: 10.1177/107327480801500406. View

15.

Hill J, McPhee J, McDade T, Zhou Z, Sullivan M, Whalen G . Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009; 115(4):741-51. DOI: 10.1002/cncr.24065. View

16.

Zerbi A, Capitanio V, Boninsegna L, Pasquali C, Rindi G, Delle Fave G . Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases. Langenbecks Arch Surg. 2010; 396(3):313-21. DOI: 10.1007/s00423-010-0712-4. View

17.

Caplin M, Pavel M, Cwikla J, Phan A, Raderer M, Sedlackova E . Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371(3):224-33. DOI: 10.1056/NEJMoa1316158. View

18.

Fjallskog M, Hessman O, Eriksson B, Janson E . Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol. 2007; 46(6):741-6. DOI: 10.1080/02841860601048388. View

19.

McEntee G, Nagorney D, Kvols L, MOERTEL C, Grant C . Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990; 108(6):1091-6. View

20.

Bilimoria K, Talamonti M, Tomlinson J, Stewart A, Winchester D, Ko C . Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008; 247(3):490-500. DOI: 10.1097/SLA.0b013e31815b9cae. View